Gröber and Buschke test
Behavioralspontaneous delayed recall score after a 5 years follow-up
NCT Number: NCT01513252
The MAPT PLUS study is a two-year extension of follow-up of the patients included in the MAPT preventive study, after completion of the interventions. Subjects in the four groups of the MAPT study will be prospectively followed. MAPT is a multicentre, randomised, placebo-controlled study, using a 4-group design with 3 treatment groups (omega 3 alone, multi-domain intervention alone, omega 3 plus multi-domain intervention, n=420 each) and a placebo group (n=420). The MAPT PLUS study will be an extension of the MAPT study and includes an annual follow-up for two years.
Looking for future studies?
Notify Me70 year and older
All sexes
Interventional
Not applicable
Bordeaux, France
The MAPT PLUS study is a follow-up of subjects initially included in an interventional study. The follow-up that we propose in this request for funding does not involve any intervention, but aims to assess the long-term effect of the interventions previously carried out during the three years of the MAPT study.
In the MAPT study, subjects are randomized into 4 groups:
The collective sessions take place in groups of 6 to 8 subjects. In the first month, two sessions a week are scheduled, and in the second month, one session a week. The first two months correspond to the intensive programme. Each session comprises 1 hour of cognitive training, 45 minutes of information on physical activity and 15 minutes of dietary advice. From the third month, sessions are held monthly and aim to consolidate the key messages and to stimulate adherence to the programme. The sessions are shorter (1 hour review of one of the domains of the intensive programme). " Booster " sessions (2 hours) are delivered at 12 and 24 months after the first sessions of the intensive programme. Twenty-minute individual interviews also take place every 6 months with the leader of the training sessions (6 interviews in the course of 3 years).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subjects who meet the following criteria will be included in the MAPT PLUS study :
Exclusion criteria
Subjects who fulfill at least one of the following criteria will not be included in the MAPT PLUS study :
spontaneous delayed recall score after a 5 years follow-up
Time frame: 2 years
Assessment of cognitive and functional performances according to the spontaneous delayed recall score(Gröber and Buschke test)
Time frame: 2 years
Assessment of cognitive and functional performances by using the Gröber and Buschke test (spontaneous delayed recall score)at 5 years after the participation to the MAPT study.
Time frame: 2 years
Evaluation of the long-term impact of MAPT study interventions on changes in markers of cerebral atrophy (overall brain volume of specific brain structures such as the hippocampus)
Time frame: 2 years
Evaluation of the long-term impact of the MAPT interventions in terms of cost-effectiveness ratio by using a medico-economic data collection
University Hospital, Toulouse
Other
A 2-years Extension Study of MAPT Trial : Evaluation of the Long Term Effects of Interventional Strategies to Prevent the Decline in Cognitive Functioning in Frail Older Adults
Acronym: MAPT-PLUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03129269
Alzheimer Disease, Brain Diseases
Toulouse, France
View Trial DetailsNCT05411393
Activities of Daily Living, Frail Elderly
Gainesville, Florida, United States
View Trial DetailsNCT06975540
Frail Elderly, Frailty
Valencia, Spain
View Trial DetailsNCT04418271
Frail Elderly, Frailty
Bad Oeynhausen, Germany
View Trial Details